Stanford



Hind Bouzid

Program Manager, Medical Genetics, Pediatrics - Genetics

Bio

BIO

Dr. Hind Bouzid received a BS and MS in Genetics from Université Paris Diderot, France. She then joined Gustave Roussy Cancer Institute, where she pursued a PhD in Hematology/Oncology, studying the genetic mechanisms underlying the progression of inherited hematologic disorders to leukemia.

She subsequently conducted research in hematopoietic stem cell gene therapy at Dana-Farber Cancer Institute, followed by postdoctoral training at Stanford University, where she studied clonal hematopoiesis in the context of neurodegenerative disease. She later transitioned to biotechnology, working in translational medicine with a focus on biomarker strategies and early-phase clinical trials for immune-mediated diseases.

Passionate about rare genetic diseases and translational medicine, Dr. Bouzid is dedicated to advancing innovative research and fostering multidisciplinary collaborations that accelerate scientific discovery and clinical progress.

HONORS AND AWARDS

- ASH abstract achievement award., 63rd American Society of Hematology conference (December 2021)
- DiGenova Postdoc Seed Grant., Stem Cell Biology and Regenerative Medicine institute, Stanford University. (June 2021)
- Postdoctoral mobility award., Philippe Foundation. (May 2019)
- 1-year PhD fellowship., Ligue Contre le Cancer. (October 2016)
- First-place recipient of a three-year PhD fellowship., French ministry of higher education, research, and innovation. (July 2013)

EDUCATION AND CERTIFICATIONS

- Certificate, UCSF-Stanford Center for Excellence in Regulatory Science and Innovation , Drug Discovery, Development and Regulation- Clinical and Industrial Drug Development (2022)
- Certificate, Stanford Graduate School of Business , Ignite Program (2021)
- PhD, Gustave Roussy Cancer Institute, Villejuif, France , Hematology/Oncology (2017)
- MSc, Université Paris Diderot, Paris, France , Genetics (2013)
- MSc, Università degli studi di Milano-Bicocca, Milan, Italy , Biology (2013)
- B.S., Université Paris Diderot, Paris, France , Life Sciences, Genetics (2011)

Publications

PUBLICATIONS

- **Anti-KIT antibody, briquilimab, induces mast cell apoptosis and depletion in nonhuman primates.** *The Journal of allergy and clinical immunology*

  Lee, S. E., Bouzid, H., Kwan, C., Sharma, A., Romo, A. R., Huang, R., Zhan, I., Banfield, C., Parnes, J. R., Smider, V. V., Yu, M., Kwon, H. S., Pang, et al

  2025; 156 (5): 1328-1340

- **TET2-mutant myeloid cells mitigate Alzheimer's disease progression via CNS infiltration and enhanced phagocytosis in mice.** *Cell stem cell*

  Matatall, K. A., Wathan, T. K., Nguyen, M., Chen, H., McDonald, A., Qi, G., Belk, J. A., Florez, M. A., Le, D. T., Olarinde, T., Vlasschaert, C., Buttigieg, M. M., Fan, et al

  2025

- **Clonal hematopoiesis is associated with protection from Alzheimer's disease.** *Nature medicine*

  Bouzid, H., Belk, J. A., Jan, M., Qi, Y., Sarnowski, C., Wirth, S., Ma, L., Chrostek, M. R., Ahmad, H., Nachun, D., Yao, W., Beiser, A., Bick, et al

  2023

- **Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis.** *Nature*

  Weinstock, J. S., Gopakumar, J., Burugula, B. B., Uddin, M. M., Jahn, N., Belk, J. A., Bouzid, H., Daniel, B., Miao, Z., Ly, N., Mack, T. M., Luna, S. E., Prothro, et al

  2023

- **Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0.** *Journal of cellular and molecular medicine*

  Manchev, V. T., Bouzid, H., Antony-Debré, I., Leite, B., Meurice, G., Droin, N., Prebet, T., Costello, R. T., Vainchenker, W., Plo, I., Diop, M., Macintyre, E., Asnafi, et al

  2017; 21 (6): 1237-1242